Zilbrysq 23 mg (Zilucoplan (Zilucoplan Sodium) SOLUTION) 23 MG

ZILBRYSQ 23 MG is a subcutaneous solution containing Zilucoplan (Zilucoplan Sodium). This medication is used to manage certain autoimmune conditions. Learn more about its uses and effects.

Strength

23 MG

Manufacturer / TM Owner

UCB CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

ZILBRYSQ 23 MG is primarily used for the treatment of autoimmune disorders. Zilucoplan, the active ingredient, works by modulating the immune system to reduce inflammation and symptoms associated with these conditions. Patients often wonder, 'What is ZILBRYSQ used for?' It is typically prescribed for conditions where immune system regulation is beneficial.

Side Effects

Common effects of ZILBRYSQ 23 MG may include localized reactions at the injection site, such as redness or swelling. Some users may experience general side effects like fatigue or mild gastrointestinal discomfort. These effects vary among individuals and are not exhaustive.

Precautions & Warnings

ZILBRYSQ 23 MG should be handled with care. Always follow the prescribed administration guidelines and store the solution as directed. Consult a healthcare provider before use, especially if you have any known allergies or underlying health conditions.

Avoid Interactions

ZILBRYSQ 23 MG may interact with other medications, particularly those that affect the immune system. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements, to avoid potential interactions.

Frequently Asked Questions

ZILBRYSQ 23 MG is used to manage certain autoimmune conditions by modulating the immune system.

ZILBRYSQ 23 MG is administered subcutaneously, typically by injection.

Common side effects may include localized reactions at the injection site and general effects like fatigue.

It is important to consult a healthcare provider before combining ZILBRYSQ 23 MG with other medications.

Follow prescribed administration guidelines and inform your healthcare provider of any allergies or health conditions.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.